← Beijing Tiantan Biological Products overview

Beijing Tiantan Biological Products vs Haemonetics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Beijing Tiantan Biological Products Corp Ltd (600161.CG)

Q3 2026
▼2▲1

Profit halved on price cuts and tax; new drug trial offers hope

  • First-half profit halved by price cuts and tax change Tiantan's first-half 2026 net profit fell about 52% to 299 million yuan, with revenue down 16.6%. The company blames medical insurance cost controls that sparked price competition in blood products, plus a January 2026 VAT change that raised its tax bill. Lower prices and higher taxes squeeze profit.

    This is the core new financial result showing why the stock is under pressure.

  • Industry-wide price war and tax hit confirmed by peers Rival Weiguang Biological also reported a near-60% profit drop and is expanding capacity despite high inventory, signaling the whole blood-products sector is oversupplied and competing on price. This confirms Tiantan's troubles are industry-wide, not company-specific, and keeps pressure on its pricing and margins.

    Shows the downturn is sector-wide, reinforcing the negative outlook for Tiantan's prices and volumes.

  • New hemophilia B drug clears Phase III trial Tiantan's subsidiary Chengdu Rongsheng completed Phase III testing of Human Coagulation Factor IX for hemophilia B and obtained the summary report. This moves a new product closer to market, which could add future revenue and reduce reliance on older products facing price pressure.

    A new pipeline advance is the main positive development this period that could support the stock.

August 2026
▼2▲1

Profit halved on price cuts and tax; new drug trial offers hope

  • First-half profit halved by price cuts and tax change Tiantan's first-half 2026 net profit fell about 52% to 299 million yuan, with revenue down 16.6%. The company blames medical insurance cost controls that sparked price competition in blood products, plus a January 2026 VAT change that raised its tax bill. Lower prices and higher taxes squeeze profit.

    This is the core new financial result showing why the stock is under pressure.

  • Industry-wide price war and tax hit confirmed by peers Rival Weiguang Biological also reported a near-60% profit drop and is expanding capacity despite high inventory, signaling the whole blood-products sector is oversupplied and competing on price. This confirms Tiantan's troubles are industry-wide, not company-specific, and keeps pressure on its pricing and margins.

    Shows the downturn is sector-wide, reinforcing the negative outlook for Tiantan's prices and volumes.

  • New hemophilia B drug clears Phase III trial Tiantan's subsidiary Chengdu Rongsheng completed Phase III testing of Human Coagulation Factor IX for hemophilia B and obtained the summary report. This moves a new product closer to market, which could add future revenue and reduce reliance on older products facing price pressure.

    A new pipeline advance is the main positive development this period that could support the stock.

Latest
▼2▲1

Profit halved on price cuts and tax; new drug trial offers hope

  • First-half profit halved by price cuts and tax change Tiantan's first-half 2026 net profit fell about 52% to 299 million yuan, with revenue down 16.6%. The company blames medical insurance cost controls that sparked price competition in blood products, plus a January 2026 VAT change that raised its tax bill. Lower prices and higher taxes squeeze profit.

    This is the core new financial result showing why the stock is under pressure.

  • Industry-wide price war and tax hit confirmed by peers Rival Weiguang Biological also reported a near-60% profit drop and is expanding capacity despite high inventory, signaling the whole blood-products sector is oversupplied and competing on price. This confirms Tiantan's troubles are industry-wide, not company-specific, and keeps pressure on its pricing and margins.

    Shows the downturn is sector-wide, reinforcing the negative outlook for Tiantan's prices and volumes.

  • New hemophilia B drug clears Phase III trial Tiantan's subsidiary Chengdu Rongsheng completed Phase III testing of Human Coagulation Factor IX for hemophilia B and obtained the summary report. This moves a new product closer to market, which could add future revenue and reduce reliance on older products facing price pressure.

    A new pipeline advance is the main positive development this period that could support the stock.

Haemonetics Corporation (HAE)

Q3 2026
▲4

CSL Plasma Deal Expands, Guidance Raised, Board Strengthened

  • CSL Plasma to roll out NexSys across all U.S. centers by end-2027 CSL Plasma now expects to complete the rollout of Haemonetics' NexSys PCS devices and Persona PLUS disposables across all its U.S. plasma collection centers by the end of 2027. This is a major expansion of the August supply deal and could significantly boost future sales and profits, though Haemonetics has not yet updated its financial guidance.

    This is the biggest new development, directly driving the stock's recent jump and future growth prospects.

  • BofA upgrades HAE to Buy, raises target to $123 on CSL deal Bank of America upgraded Haemonetics to Buy from Neutral and raised its price target to $123 from $92, citing the CSL supply deal. The analyst expects the deal to lift organic revenue growth, operating margins, and earnings per share over the next several years, which supports a higher stock price.

    This is a new analyst action that validates the CSL deal's positive impact and can attract more investors.

  • Q1 earnings beat, fiscal 2027 guidance raised Haemonetics reported first-quarter revenue of $339 million, up 6% organically, and raised its full-year fiscal 2027 guidance. Adjusted EPS rose 4% to $1.14. Strong plasma and MedSurg growth, plus the Persona PLUS rollout, drove the beat and higher outlook, signaling healthy business momentum.

    This is a new earnings report that directly affects investor expectations for future profits.

  • New board member brings operational and strategic expertise Haemonetics elected Martin Madaus to its Board of Directors. Dr. Madaus has over 30 years of leadership experience in diagnostics and life sciences, including CEO roles at Ortho Clinical Diagnostics and Millipore. His expertise is expected to support growth and long-term value creation, a positive but gradual influence.

    This is a new governance change that could improve strategic direction, though its impact is longer-term.

September 2026
▲4

CSL Plasma Deal Expands, Guidance Raised, Board Strengthened

  • CSL Plasma to roll out NexSys across all U.S. centers by end-2027 CSL Plasma now expects to complete the rollout of Haemonetics' NexSys PCS devices and Persona PLUS disposables across all its U.S. plasma collection centers by the end of 2027. This is a major expansion of the August supply deal and could significantly boost future sales and profits, though Haemonetics has not yet updated its financial guidance.

    This is the biggest new development, directly driving the stock's recent jump and future growth prospects.

  • BofA upgrades HAE to Buy, raises target to $123 on CSL deal Bank of America upgraded Haemonetics to Buy from Neutral and raised its price target to $123 from $92, citing the CSL supply deal. The analyst expects the deal to lift organic revenue growth, operating margins, and earnings per share over the next several years, which supports a higher stock price.

    This is a new analyst action that validates the CSL deal's positive impact and can attract more investors.

  • Q1 earnings beat, fiscal 2027 guidance raised Haemonetics reported first-quarter revenue of $339 million, up 6% organically, and raised its full-year fiscal 2027 guidance. Adjusted EPS rose 4% to $1.14. Strong plasma and MedSurg growth, plus the Persona PLUS rollout, drove the beat and higher outlook, signaling healthy business momentum.

    This is a new earnings report that directly affects investor expectations for future profits.

  • New board member brings operational and strategic expertise Haemonetics elected Martin Madaus to its Board of Directors. Dr. Madaus has over 30 years of leadership experience in diagnostics and life sciences, including CEO roles at Ortho Clinical Diagnostics and Millipore. His expertise is expected to support growth and long-term value creation, a positive but gradual influence.

    This is a new governance change that could improve strategic direction, though its impact is longer-term.

Latest
▲4

CSL Plasma Deal Expands, Guidance Raised, Board Strengthened

  • CSL Plasma to roll out NexSys across all U.S. centers by end-2027 CSL Plasma now expects to complete the rollout of Haemonetics' NexSys PCS devices and Persona PLUS disposables across all its U.S. plasma collection centers by the end of 2027. This is a major expansion of the August supply deal and could significantly boost future sales and profits, though Haemonetics has not yet updated its financial guidance.

    This is the biggest new development, directly driving the stock's recent jump and future growth prospects.

  • BofA upgrades HAE to Buy, raises target to $123 on CSL deal Bank of America upgraded Haemonetics to Buy from Neutral and raised its price target to $123 from $92, citing the CSL supply deal. The analyst expects the deal to lift organic revenue growth, operating margins, and earnings per share over the next several years, which supports a higher stock price.

    This is a new analyst action that validates the CSL deal's positive impact and can attract more investors.

  • Q1 earnings beat, fiscal 2027 guidance raised Haemonetics reported first-quarter revenue of $339 million, up 6% organically, and raised its full-year fiscal 2027 guidance. Adjusted EPS rose 4% to $1.14. Strong plasma and MedSurg growth, plus the Persona PLUS rollout, drove the beat and higher outlook, signaling healthy business momentum.

    This is a new earnings report that directly affects investor expectations for future profits.

  • New board member brings operational and strategic expertise Haemonetics elected Martin Madaus to its Board of Directors. Dr. Madaus has over 30 years of leadership experience in diagnostics and life sciences, including CEO roles at Ortho Clinical Diagnostics and Millipore. His expertise is expected to support growth and long-term value creation, a positive but gradual influence.

    This is a new governance change that could improve strategic direction, though its impact is longer-term.